21.05.2013 - Dutch cancer experts have found an enzyme that seems to induce cancer senescence.
When oncogenes are activated inside a cell, they normally mobilise tumour suppressor networks which can act like a brake to cancer through a process termed oncogene-induced senescence (OIS). They withdraw proliferating cells almost irreversibly, providing protection against malignant transformation. Now, a research team led by Daniel Peeper from the Netherland’s Cancer Institute in Amsterdam has identified a metabolic gate-keeper of the process.
Using metabolic and functional analyses of melanoma cells carrying the common BRAFV600E mutation, the team of Dutch, Scottish, Belgian, Spanish, Israeli and US researchers identified the TCA enzyme pyruvate dehydrogenase (PDH) as a crucial mediator of cancer senescence. BRAFV600E-induced senescence was accompanied by simultaneous suppression of the PDH-inhibitory enzyme pyruvate dehydrogenase kinase 1 (PDK1) and induction of the PDH-activating enzyme pyruvate dehydrogenase phosphatase 2 (PDP2). The resulting combined activation of PDH enhanced the use of pyruvate in the tricarboxylic acid cycle, causing increased respiration and redox stress.
Enforced normalisation of either PDK1 or PDP2 expression levels inhibited PDH and abrogated oncogene-induced senescence. Depletion of PDK1 eradicated melanoma subpopulations resistant to targeted BRAF inhibition, and caused regression of established melanomas. The results suggest a mechanistically new therapeutic route to induce cancer senescence and stop tumour cell proliferation at its earliest stages.
12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.
09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.
29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.
24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.
20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.